QUOTE AND NEWS
Benzinga  Mar 20  Comment 
Eli Lilly and Co (NYSE: LLY) unveiled one of the largest biotech collaborations in China to date in a deal aimed at cancer drugs. Lilly changed hands recently at $74.67, up $0.45. Indianapolis-based Lilly will team up with China-based...
GenEng News  Mar 20  Comment 
Eli Lilly will join Innovent Biologics to co-develop and co-commercialize at least three cancer treatments over the next decade, in a deal that could generate up to $456 million for the Chinese biopharma. Under their agreement, Innovent will...
TheStreet.com  Mar 19  Comment 
NEW YORK (TheStreet) -- Eli Lilly shares are up 1.28% to $74.48 in trading on Thursday after the pharmaceutical and animal health company agreed to an exclusive license and collaboration agreement with Hanmi Pharmaceuticals to develop...
GenEng News  Mar 19  Comment 
Eli Lilly will join in developing and commercializing Hanmi Pharmaceutical's Phase I compound HM71224 for autoimmune and other diseases, in a deal that could generate up to $690 million, plus royalties, for Hanmi. HM71224 is an oral Bruton's...
Market Intelligence Center  Mar 13  Comment 
Eli Lilly and Co (LLY) is an excellent choice for either a diagonal spread or a covered call expiring in May. '15 at the $70.00 level according to MarketIntelligenceCenter.com’s patented algorithms.A covered call on Eli Lilly for a net debit of...
Market Intelligence Center  Mar 10  Comment 
After Monday’s trading in Eli Lilly and Co (LLY) MarketIntelligenceCenter.com's option trade-picking algorithms uncovered a trade that offers a 3.83% or 21.16% (for comparison purposes only), while providing 3.10% downside protection. The trade...
Wall Street Journal  Mar 6  Comment 
A German court ruled that Eli Lilly & Co. cannot prevent a competitor from selling a generic form of its key Alimta cancer drug once the patent expires this December.
Jutia Group  Mar 6  Comment 
[Reuters - UK Focus] - Eli Lilly has lost a patent case in Germany over its blockbuster Alimta lung cancer drug to generic producer Actavis (NYSE: ACT - news) , hitting the U.S. drugmaker's future sales hopes for the medicine. The ruling...
Jutia Group  Mar 6  Comment 
[Reuters - UK Focus] - Eli Lilly has lost a patent case in Germany over its blockbuster Alimta lung cancer drug to generic producer Actavis (NYSE: ACT - news) , hitting the U.S. drugmaker's future sales hopes for the medicine. The ruling...




 

Very nice site!

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki